BioLargo Subsidiary Clyra Medical Technologies Secures First Stocking Order with Advanced Solution for ViaCLYR(TM) Wound Irrigation Solution

Rhea-AI Summary

BioLargo (OTCQX:BLGO) subsidiary Clyra Medical Technologies received its first commercial stocking order from Advanced Solution for ViaCLYR, marking Clyra's transition from development-stage to early revenue-generating commercial distribution on February 9, 2026. The order initiates national availability via Advanced Solution's distribution platform to hospitals and clinics. Clyra holds FDA 510(k) clearance, operates under ISO 13485-certified quality systems, and reports validated manufacturing and clinical evaluations supporting use in acute and chronic wounds.

Positive

• First commercial stocking order received from Advanced Solution
• Initiation of national distribution to hospitals and clinics in the US
• Product is FDA 510(k) cleared and manufactured under ISO 13485 systems

Negative

• None.

Initial Distribution Launch Marks Transition to Revenue-Generating Operations

WESTMINSTER, CALIFORNIA / ACCESS Newswire / February 9, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences innovator, announced today that its subsidiary, Clyra Medical Technologies, Inc., has received its first commercial stocking order from Advanced Solution, LLC for ViaCLYR™, Clyra's FDA-cleared wound irrigation solution. The order marks the start of commercial distribution and represents Clyra's transition from development-stage operations to early revenue generation.

The stocking order initiates product availability through Advanced Solution's national distribution platform, supporting sales to hospitals, clinics, and healthcare providers across the United States. BioLargo views this milestone as the first in a series of planned commercial and revenue-related announcements as Clyra advances its market rollout.

ViaCLYR™ is a highly effective, tissue safe, long-acting wound irrigation solution that can be used for acute and chronic wounds and burns. This unique, clear, odorless, non-irritating solution is 510(k) cleared by the FDA and indicated for acute and chronic wounds. It has an extremely high antimicrobial activity as a preservative in solution with over 99.9999% kill rate (up to 7 log reduction) with sustained efficacy up to 72 hours.

"This initial commercial order reflects years of disciplined development, regulatory execution, and commercial preparation," said Steve Harrison, Clyra's Chief Executive Officer. "With ViaCLYR™ now entering the distribution channel, we are beginning the transition from innovation to execution, laying the groundwork for scalable revenue growth as adoption expands."

Dennis P. Calvert, Chairman of Clyra Medical Technologies and President and CEO of BioLargo, Inc., added, "This milestone represents a tangible step forward in BioLargo's strategy of developing differentiated technologies and advancing them into commercial markets through strong partnerships. We believe Clyra is well positioned to build momentum as product availability expands and market awareness grows."

Clyra's commercial readiness reflects the completion of key foundational elements, including FDA 510(k) clearance, implementation of ISO 13485-certified quality systems, validated manufacturing processes, and clinical evaluations supporting real-world use. As distribution begins, Clyra plans to advance additional commercialization initiatives and expand its product portfolio over time.

About Clyra Medical Technologies

Clyra Medical Technologies, Inc., a partially-owned subsidiary of BioLargo, Inc., focuses on infection control and advanced wound care. Founded in 2012, the company develops and commercializes wound care solutions based on its proprietary Copper-Iodine Complex Technology. Clyra's product portfolio features FDA-cleared medical devices that leverage this patented technology to deliver superior wound care outcomes. The company continues to advance its research and development efforts, exploring expanded indications for its unique formulations and their synergistic applications with complementary wound care dressings and mechanical devices. Through strategic partnerships with leading distribution and marketing organizations, Clyra ensures its innovative products reach healthcare providers and patients who need them most.

About Advanced Solution

Advanced Solution LLC (https://advancedsolution.health) specializes in advanced wound care biologics, regenerative technologies, and medical devices. As an FDA-registered Tissue Dispensary Intermediary (TDI), Advanced Solution partners with healthcare providers, hospitals, and clinics across the United States to deliver innovative, outcomes-driven products that improve patient care and operational efficiency. Headquartered in Carlisle, Pennsylvania, Advanced Solution represents a portfolio of market-leading brands and collaborates closely with manufacturers, clinicians, and healthcare organizations to bring cutting-edge therapies to market. With a focus on compliance, education, and strategic commercialization, the company continues to set the standard for excellence in distribution and partnership within the wound care and life sciences industries.

About BioLargo, Inc.

BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

SOURCE: BioLargo, Inc.

View the original press release on ACCESS Newswire

FAQ

What does the Advanced Solution stocking order mean for BioLargo (BLGO)?

It marks Clyra's initial transition to revenue-generating commercial distribution. According to the company, the order initiates national availability through Advanced Solution's platform to hospitals, clinics, and healthcare providers, supporting broader market rollout and future commercial announcements.

Is ViaCLYR cleared by the FDA for wound care (BLGO)?

Yes. ViaCLYR is cleared via FDA 510(k) for use in acute and chronic wounds. According to the company, the product is a tissue-safe, clear, odorless irrigation solution with documented antimicrobial activity and clinical evaluations supporting real-world use.

How will distribution through Advanced Solution affect ViaCLYR availability (BLGO)?

Distribution via Advanced Solution initiates national channel access to hospitals and clinics across the US. According to the company, this partnership places ViaCLYR on a distributor platform that supports sales, compliance-focused commercialization, and scaling of product availability.

What evidence of manufacturing and quality does Clyra have for ViaCLYR (BLGO)?

Clyra reports ISO 13485-certified quality systems and validated manufacturing processes. According to the company, these foundational elements accompany FDA 510(k) clearance and clinical evaluations to support product launch and regulatory-compliant commercial distribution.

Does the press release disclose revenue or order size from the stocking order (BLGO)?

No specific revenue figures or order size were disclosed for the stocking order. According to the company, the announcement describes the order as the start of commercial distribution and the beginning of early revenue generation without providing dollar amounts.